[go: up one dir, main page]

ATE501735T1 - Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen - Google Patents

Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen

Info

Publication number
ATE501735T1
ATE501735T1 AT04806560T AT04806560T ATE501735T1 AT E501735 T1 ATE501735 T1 AT E501735T1 AT 04806560 T AT04806560 T AT 04806560T AT 04806560 T AT04806560 T AT 04806560T AT E501735 T1 ATE501735 T1 AT E501735T1
Authority
AT
Austria
Prior art keywords
phagocytic
minicells
bacterially
gene delivery
cells via
Prior art date
Application number
AT04806560T
Other languages
English (en)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Application granted granted Critical
Publication of ATE501735T1 publication Critical patent/ATE501735T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
AT04806560T 2003-12-09 2004-12-08 Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen ATE501735T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52776403P 2003-12-09 2003-12-09
PCT/IB2004/004406 WO2005056749A2 (en) 2003-12-09 2004-12-08 Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells

Publications (1)

Publication Number Publication Date
ATE501735T1 true ATE501735T1 (de) 2011-04-15

Family

ID=34676775

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04806560T ATE501735T1 (de) 2003-12-09 2004-12-08 Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen

Country Status (15)

Country Link
US (3) US9169495B2 (de)
EP (2) EP2295084A1 (de)
JP (1) JP4332558B2 (de)
CN (2) CN1913923B (de)
AT (1) ATE501735T1 (de)
AU (1) AU2004297414C1 (de)
CA (1) CA2549840C (de)
DE (1) DE602004031870D1 (de)
DK (1) DK1694361T3 (de)
ES (1) ES2362881T3 (de)
HK (1) HK1095090A1 (de)
NZ (1) NZ547983A (de)
PL (1) PL1694361T3 (de)
PT (1) PT1694361E (de)
WO (1) WO2005056749A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102172406B (zh) * 2001-10-15 2013-03-13 恩吉尼克分子传递私人有限公司 用作体外和体内dna转染与基因治疗载体的完整微细胞
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
ATE501735T1 (de) 2003-12-09 2011-04-15 Engeneic Molecular Delivery Pty Ltd Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
HUE025292T2 (en) 2004-02-02 2016-02-29 Engeneic Molecular Delivery Pty Ltd Preparations and Methods for Targeted Mammalian Cells for In Vitro and In vivo Drug Delivery with Minimal Cell Bacterial Cells
US8691963B2 (en) 2004-08-26 2014-04-08 Engeneic Molecular Delivery Pty. Ltd. Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
PT2040725E (pt) 2006-06-23 2014-04-24 Engeneic Molecular Delivery Pty Ltd Distribuição dirigida de fármacos, ácidos nucleicos terapêuticos e ácidos nucleicos funcionais a células de mamífero através de células bacterianas mortas intactas
CA2933978C (en) 2007-03-30 2018-08-21 Engeneic Molecular Delivery Pty. Ltd. Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
WO2009158364A1 (en) 2008-06-25 2009-12-30 Vaxiion Therapeutics, Inc. Regulated genetic suicide mechanism compositions and methods
CA2827443C (en) 2011-02-15 2021-07-06 Vaxiion Therapeutics, Inc. Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
SG10201601349XA (en) * 2011-12-13 2016-03-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
CN113577260A (zh) 2012-10-02 2021-11-02 瓦克星治疗有限责任公司 免疫调节性小细胞及使用方法
US9017698B2 (en) * 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
NZ718148A (en) * 2013-10-04 2022-02-25 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
US10328159B2 (en) 2014-10-03 2019-06-25 Engenic Molecular Delivery Pty Ltd. Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
KR102687638B1 (ko) 2015-08-04 2024-07-22 벡션 테라퓨틱스 엘엘씨 이온화 방사선 조사 멸균된 박테리아 미니세포 기반 생물 약제
US20190328783A1 (en) * 2016-04-15 2019-10-31 Cellectis A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
US10894093B2 (en) 2016-04-15 2021-01-19 Cellectis Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
MY198782A (en) 2016-10-06 2023-09-27 Engeneic Molecular Delivery Pty Ltd Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
EP3544626A1 (de) 2016-11-23 2019-10-02 Vaxiion Therapeutics, LLC Immunmodulatorische und onkolytische minizellen und verfahren zur verwendung
JP2021532106A (ja) 2018-07-23 2021-11-25 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 細菌由来ミニ細胞を含む組成物およびそれを使用する方法
WO2020222161A1 (en) * 2019-05-01 2020-11-05 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived intact minicells for theranostic applications

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496778A (en) 1983-10-03 1985-01-29 Exxon Research & Engineering Co. Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5221479A (en) * 1991-02-15 1993-06-22 Fuji Photo Film Co., Ltd. Filtration system
EP1400536A1 (de) 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
NZ288883A (en) 1994-07-11 1998-12-23 Univ Texas Conjugates comprising coagulation factors
US6025197A (en) 1997-03-19 2000-02-15 Zymogenetics, Inc. Secreted salivary zsig32 polypeptides
US20030004123A1 (en) * 1997-06-26 2003-01-02 Boucher Richard C. Targeted gene transfer using G protein coupled receptors
AU754425B2 (en) * 1997-09-15 2002-11-14 Genetic Immunity, Llc. Method of delivering genes to antigen presenting cells of the skin
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
BR0009884A (pt) 1999-04-21 2002-01-08 American Home Prod Processos e composições para a inibição da função das sequências de polinucleotìdeos
WO2002016590A2 (en) 2000-08-21 2002-02-28 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
WO2002072759A2 (en) * 2001-03-07 2002-09-19 Children's Medical Center Corporation Method to screen peptide display libraries using minicell display
US7011946B2 (en) 2001-05-22 2006-03-14 Trustees Of Tufts College In vivo assay for identification of antimicrobial agents
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20030194714A1 (en) 2001-06-05 2003-10-16 Sabbadini Roger A. Minicell-based transformation
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
CN102172406B (zh) * 2001-10-15 2013-03-13 恩吉尼克分子传递私人有限公司 用作体外和体内dna转染与基因治疗载体的完整微细胞
EP2390308A1 (de) 2002-02-25 2011-11-30 Vaxiion Therapeutics Inc Minizell-Zusammensetzungen und Verfahren
US20030203481A1 (en) * 2002-02-25 2003-10-30 Surber Mark W. Conjugated minicells
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
ATE501735T1 (de) 2003-12-09 2011-04-15 Engeneic Molecular Delivery Pty Ltd Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US8691963B2 (en) 2004-08-26 2014-04-08 Engeneic Molecular Delivery Pty. Ltd. Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
CA2591565C (en) 2004-12-17 2014-06-10 Beth Israel Deaconess Medical Center Compositions for bacterial mediated gene silencing and methods of using same
PT2040725E (pt) 2006-06-23 2014-04-24 Engeneic Molecular Delivery Pty Ltd Distribuição dirigida de fármacos, ácidos nucleicos terapêuticos e ácidos nucleicos funcionais a células de mamífero através de células bacterianas mortas intactas

Also Published As

Publication number Publication date
EP1694361B1 (de) 2011-03-16
CN1913923A (zh) 2007-02-14
EP2295084A1 (de) 2011-03-16
CA2549840C (en) 2012-03-20
US20180369416A1 (en) 2018-12-27
CA2549840A1 (en) 2005-06-23
ES2362881T3 (es) 2011-07-14
WO2005056749A3 (en) 2005-10-13
CN1913923B (zh) 2010-12-08
EP1694361A2 (de) 2006-08-30
AU2004297414B2 (en) 2008-10-30
NZ547983A (en) 2009-05-31
PL1694361T3 (pl) 2011-08-31
AU2004297414A1 (en) 2005-06-23
US20150343092A1 (en) 2015-12-03
CN101954095A (zh) 2011-01-26
US20070237744A1 (en) 2007-10-11
PT1694361E (pt) 2011-06-27
WO2005056749A2 (en) 2005-06-23
DK1694361T3 (da) 2011-06-06
AU2004297414C1 (en) 2009-06-25
US9987377B2 (en) 2018-06-05
US10583200B2 (en) 2020-03-10
US9169495B2 (en) 2015-10-27
CN101954095B (zh) 2013-03-13
JP4332558B2 (ja) 2009-09-16
JP2007534310A (ja) 2007-11-29
DE602004031870D1 (de) 2011-04-28
HK1095090A1 (en) 2007-04-27
EP1694361A4 (de) 2006-12-13

Similar Documents

Publication Publication Date Title
ATE501735T1 (de) Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen
O’Hagan et al. Photocleavable ortho-nitrobenzyl-protected DNA architectures and their applications
Nie et al. Versatile and ultrasensitive electrochemiluminescence biosensor for biomarker detection based on nonenzymatic amplification and aptamer-triggered emitter release
Gnaccarini et al. Site-specific cleavage of RNA by a metal-free artificial nuclease attached to antisense oligonucleotides
Pei et al. Behavior of polycatalytic assemblies in a substrate-displaying matrix
Zeng et al. Fine tuning of CpG spatial distribution with DNA origami for improved cancer vaccination
US20200048606A1 (en) Methods for Selection and Generation of Genome Edited T Cells
ATE465250T1 (de) Saure alpha-glukosidase und fragmente davon
CY1118437T1 (el) Στοχευομενη απελευθερωση φαρμακων θεραπευτικων νουκλεϊνικων οξεων και λειτουργικων νουκλεϊνικων οξεων σε κυτταρα θηλαστικου μεσω ανεπαφων θανατωμενων βακτηριακων κυτταρων
DK2253718T3 (da) Fast overflade til biomolekylafgivelse og analyse med høj omsætning
CN107384894A (zh) 功能化氧化石墨烯高效运载CRISPR/Cas9用于基因编辑的方法
PT2284266E (pt) Siarn contra tp53
AR069253A1 (es) Plantas transgenicas que expresan el acido nucleico de ossik1 y moduladores para aumentar la tolerancia a estres
WO2004065613A3 (en) Inducible small interfering rna (sirna) expression constructs for targeted gene silencing
DE60324430D1 (de) Methode um rekombinante proteine in cho zellen zu exprimieren
JP2010500029A5 (de)
EP1690937A4 (de) Verfahren zur konstruktion einer transgenen dendritischen zelle
Kubo et al. Lipid-conjugated 27-nucleotide double-stranded RNAs with dicer-substrate potency enhance RNAi-mediated gene silencing
ATE420157T1 (de) Zielgerichtete genveraenderung mit parvoviralen vektoren
AU2014208251B2 (en) Carbohydrate conjugates as delivery agents for oligonucleotides
GB9816138D0 (en) Organic compounds
Arnaoty et al. Novel approach for the development of new antibodies directed against transposase-derived proteins encoded by human neogenes
Aten et al. Electrostatic accumulation and release of DNA using a micromachined lance
Alon et al. Engineering a DNAzyme-based operon system for the production of DNA nanoscaffolds in living bacteria
MXPA03011013A (es) Constructos de acidos nucleicos utiles para la produccion regulada por glucosa de insulina humana en lineas de celulas somaticas.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1694361

Country of ref document: EP